Somewhat realistic that it could achieve fda approval for ptsd treatment by 2024. although it would probably be like you have to go do it at a clinic, at least at first
2024 can happen for MDMA, though. MAPS has completed (I believe) Phase 3B for comparing PTSD.
It’s happening, but slowly. I fully expect these wonderful molecules to be widely available in clinical settings within 5 years, including LSD and ibogaine (which seems particularly promising for addiction treatment)